Market closedADR
Compass Pathways/$CMPS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Ticker
$CMPS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
166
Website
Compass Pathways Metrics
BasicAdvanced
$286M
-
-$2.30
2.29
-
Price and volume
Market cap
$286M
Beta
2.29
52-week high
$10.31
52-week low
$2.69
Average daily volume
1.1M
Financial strength
Current ratio
5.918
Quick ratio
5.495
Long term debt to equity
16.132
Total debt to equity
20.811
Interest coverage (TTM)
-35.08%
Management effectiveness
Return on assets (TTM)
-40.11%
Return on equity (TTM)
-81.55%
Valuation
Price to book
1.37
Price to tangible book (TTM)
1.37
Price to free cash flow (TTM)
-1.75
Growth
Earnings per share change (TTM)
-0.98%
3-year earnings per share growth (CAGR)
8.62%
What the Analysts think about Compass Pathways
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Compass Pathways Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Compass Pathways Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Compass Pathways News
AllArticlesVideos
This Is a Test From GlobeNewswire
GlobeNewsWire·6 days ago
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire·1 week ago
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $286M as of April 04, 2025.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of April 04, 2025.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 2.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.